Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 41Active not recruiting 33Completed 14Terminated 4Not yet recruiting 2Withdrawn 1Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

pembrolizumab 20Magnetic Resonance Spectroscopy 13Specimen Handling 12Cyclophosphamide 11fludarabine 10Radiotherapy 9Biopsy 9atezolizumab 7Nivolumab 7Radiation 6Gemcitabine 5fludarabine phosphate 4aldesleukin 4Prednisone 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4ALT-803 4lenvatinib 3avelumab 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3Paclitaxel 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × 1,2-diaminocyclohexaneplatinum II citrate × 1 year × Clear all
NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡